Our leadership and scientific advisory board bring deep entrepreneurial, medical, scientific and operational experience of developing novel pharmaceutical products
Krishnan Nandabalan, Ph.D., has served as President, Chief Executive Officer, and Chairman of the Board of Directors of Invea Therapeutics, Inc. since October 2021. He has served as the President and CEO of InveniAI LLC since 2017. Dr. Nandabalan also previously served as a member of the board of directors of BioXcel, LLC (formerly BioXcel Corporation), a company he co-founded, from 2017 to September 2023. Dr. Nandabalan also previously served as BioXcel LLC’s President, Secretary, and Director from 2005 to September 2023 and Chief Scientific Officer from 2014 to September 2023. Dr. Nandabalan holds a B.Sc. and M.Sc. in agricultural science from Tamil Nadu Agricultural University, India, and a Ph.D. in biochemistry and molecular biology from the Indian Institute of Science, India.
Ramkesh Meena, MD
Ramkesh Meena is a Medical graduate and MD (Clinical Pharmacology) from All India Institute of Medical Sciences, New Delhi, with clinical practice experience of around 6 years. He brings with him ~15 years of management consulting experience advising life sciences companies to transform growth across the value chain. He started his management consulting journey with life sciences boutique consulting firm BioXcel Corporation, where he spent ~5 years establishing best-in-class consulting practices. Thereafter, he joined Deloitte Consulting’s Monitor Deloitte (Strategy Consulting) practice, where he focused on scaling life sciences and health care consulting practices, combining scientific grounding with strategic implications to deliver integrated innovative transformative solutions to support growth for >20 pharma, biotech, and medical companies. He also served as the Chief Medical Officer to lead Deloitte’s medical and scientific practices, such as therapy area strategy, next-generation therapies, R&D, etc., and acted as the primary medical advisor for Deloitte management on all policy matters for India. He completed his ~10 years at Deloitte in December 2023, just before co-founding RenaissThera. His aim is to leverage his consulting experiences, which include advising clients on portfolio growth journeys and establishing R&D and commercial capabilities, to develop innovative therapies for underserved populations.
Sudhir Nagarajan
Sudhir has grown various businesses from the ground up, both as a founder/entrepreneur and as part of the founding team within larger organizations, over the past 3 decades. His experience spans domains as varied as Fashion and Apparel, Food and Beverages, Hospitality, FMCG, Real Estate, and now Biotech. He has worked in 4 continents, and has built customer relationships in all 5. I am excited about the new challenge of the biotech space and the opportunity that RenaissThera focuses on.